Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocera Therapeutics OCRX

Healthcare Biotechnology
"Ocera Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of proprietary compounds to treat acute and chronic orphan liver disease."

Recent & Breaking News (NDAQ:OCRX)

Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016

GlobeNewswire October 24, 2016

Ocera to Present at the 2016 BIO Investor Forum

GlobeNewswire October 10, 2016

Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure

GlobeNewswire September 21, 2016

Ocera to Present at the Ladenburg Thalmann 2nd Annual Healthcare Conference

GlobeNewswire September 20, 2016

Ocera Initiates Phase 1 Clinical Study of Orally Available OCR-002 in Patients with Cirrhosis for the Prevention of Hepatic Encephalopathy

GlobeNewswire September 19, 2016

Ocera Announces Management Transition

GlobeNewswire September 15, 2016

Ocera Therapeutics Reports Second Quarter 2016 Financial Results and Company Update

GlobeNewswire August 3, 2016

Ocera to Present at the JMP Securities Life Sciences Conference

GlobeNewswire June 13, 2016

Genticel Announces Completion of Two Major Milestones in Preparation for Phase 3 Program of GTL001

GlobeNewswire June 13, 2016

Ocera to Present at the Jefferies 2016 Healthcare Conference

GlobeNewswire May 31, 2016

Ocera to Present at the 2016 BIO International Convention

GlobeNewswire May 26, 2016

Ocera Therapeutics Reports First Quarter 2016 Financial Results and Pipeline Progress

GlobeNewswire April 29, 2016

Ocera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress(TM) 2016 of the European Association for the Study of the Liver (EASL)

GlobeNewswire April 15, 2016

Ocera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of Hepatology

GlobeNewswire April 11, 2016

Ocera to Present at the 15th Annual Needham Healthcare Conference

GlobeNewswire April 5, 2016

LifeSci Capital Initiates Coverage of Ocera Therapeutics

Accesswire March 24, 2016

Ocera Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update

GlobeNewswire March 3, 2016

Ocera to Present at the Cowen and Company 36th Annual Health Care Conference

GlobeNewswire February 29, 2016

Ocera to Present at the 18th Annual BIO CEO & Investor Conference

GlobeNewswire February 2, 2016

Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy

GlobeNewswire January 8, 2016